Charles Zacharchuk

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

Harold J. Burstein, Yan Sun, Luc Dirix et al. · Journal of Clinical Oncology · 2010 · 527 citations · Full text

Medicine, Oncology, Pharmacology +17

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

Lecia V. Sequist, Benjamin Besse, Thomas J. Lynch et al. · Journal of Clinical Oncology · 2010 · 426 citations · Full text

Medicine, Oncology, Pharmacology +16

Programmed T lymphocyte death. Cell activation- and steroid-induced pathways are mutually antagonistic.

Charles Zacharchuk, Mladen Merćep, Pradip K. Chakraborti et al. · The Journal of Immunology · 1990 · 318 citations · Full text

Life Sciences, Cell Biology, Immunology +17

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Kwok-K. Wong, Paula M. Fracasso, Ronald M. Bukowski et al. · Clinical Cancer Research · 2009 · 303 citations · Full text

Medicine, Oncology, Pharmacology +13

Lack of a Role for Jun Kinase and AP-1 in Fas-Induced Apoptosis

Joi M. Lenczowski, Lourdes Domínguez, Astrid Eder et al. · Molecular and Cellular Biology · 1997 · 249 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17